We believe transparency is an important part of our ongoing collaboration with the health care community, helping to build a community of trust and respect with healthcare professionals, patients, industry peers, stockholders and the public.
EFPIA
Biogen strongly believes that collaboration with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) is crucial to discover, develop and deliver innovative therapies that improve the lives of patients. At the same time, we believe that these interactions must be conducted openly and transparently.
As a member of EFPIA (the European Federation of Pharmaceutical Industries and Associations) and the ABPI (Association of the British Pharmaceutical Industry), Biogen is proud to endorse and uphold the EFPIA Disclosure Code and the ABPI Code of Practice disclosure requirements. In line with the codes, Biogen has been collecting all payments and contributions made to HCPs and HCOs since January 2015.
These payments are published on Disclosure UK, the ABPI's disclosure database, on their website.
Biogen-61246 v2 Date of Preparation: June 2021
Patient Organisation Support
Biogen is proud to work with Patient Organisations and support their efforts to improve the lives of their members and raise awareness of serious medical conditions. We are aligned in enhancing patient advocacy and supporting medical research for the discovery of effective therapies. Below is a breakdown of the support Biogen has provided to Patient Organisations in the UK.
2020
In 2020 Biogen contributed £663,141.67 to UK Patient Organisations.
| Patient organisation | Project | Amount of support |
|---|---|---|
| Alzheimer Scotland | G&D: The SEADD Programme (Invoice: 0000006770) | £99,000.00 |
| Alzheimer’s Society | G&D: Dementia Connect & COVID-19 Support (Invoice: PSI179182) | £89,131.00 |
| Genetic Alliance UK Ltd | Industry Membership 2019/20 | £11,000.00 |
| Genetic Alliance UK Ltd | Industry Membership 2020/21 | £12,000.00 |
| MS Society | G&D: Towards MS Physical Activity Specialist (INV0003074) | £91,902.00 |
| MS Society | G&D: Core Case for Investment in MS Services (INV0003081) | £7,166.00 |
| MS Society | Fee: Attendance at PSP Ad Board Meeting Aug 2020 | £220.00 |
| MS Trust | G&D: Training Programme - MS Therapists & Paediatric MS Nurses (Invoice: 5600) | £10,000.00 |
| MS Trust | G&D: Specialist Nurse Programme 2020 (Invoice: 5604) | £35,372.00 |
| MS Trust | G&D COVID-19 Emergency Funding (Invoice: 5605) | £29,150.00 |
| MS Trust | Fee: Attendance at PSP Ad Board Meeting Aug 2020 | £344.00 |
| MS Trust | Fee: Participation in Ad Board - Emotional Journey in MS Series | £1,146.67 |
| Muscular Dystrophy UK | Sponsorship (INV000300) | £5,000.00 |
| National Rheumatoid Arthritis Society (NRAS) | Corporate Membership 2020-21 | £10,000.00 |
| National Rheumatoid Arthritis Society (NRAS) | Covid19 Response Funding | £10,000.00 |
| Retina UK | G&D: Covid 19 Support (Invoice: 16991/0411) | £50,000.00 |
| SHIFT MS | G&D: MS Reporters Series (Invoice: 0056) | £28,000.00 |
| SHIFT MS |
G&D: 9-to-5 Video Series (Invoice: 0063) | £29,500.00 |
| SHIFT MS |
SG&D: Co-Vid Companion (Invoice: 0067) | £26,450.00 |
| SHIFT MS | Sponsorship: 'Day one' Web series (Invoice: 0076) | £29,000.00 |
| SHIFT MS | Sponsorship: 'Building resilience through Collaboration' (Invoice: 0077) | £28,000.10 |
| Spinal Muscular Atrophy Support UK | G&D: Covid 19 Emergency funding (Invoice: 48/2020) | £39,124.00 |
| The Neurological Alliance | Corporate Membership | £10,748.00 |
| The Neurological Alliance | Industry Reference Group | £10,888.00 |
Biogen-61246 v2 Date of Preparation: June 2021
Healthcare Professional Support
Biogen strongly believes that collaboration with Healthcare Professionals (HCPs) is crucial to discover, develop and deliver innovative therapies that improve the lives of patients. At the core of this relationship is the ability to share knowledge in order to improve patient outcomes. At the same time, we believe that Biogen’s interactions with HCPs must be conducted openly and transparently, as embodied by the principles of the EFPIA Disclosure Code and the ABPI Code of Practice.
To this end, Biogen supports the decision to publically disclose the payments and contributions made to HCPs. By committing ourselves to the highest standards of integrity and accountability, we look to lead our industry in building trust with the communities we serve.
Payments made from 2015 onwards are published on Disclosure UK, the ABPI's disclosure database, on their website.
Biogen-61246 v2 Date of Preparation: June 2021